{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:50:03Z","timestamp":1788778203497,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Sivas Cumhuriyet \u00dcniversitesi,T\u00fcrkiye","award":["T-2021-915"],"award-info":[{"award-number":["T-2021-915"]}]},{"name":"Sivas Cumhuriyet \u00dcniversitesi,T\u00fcrkiye","award":["T-2021-915"],"award-info":[{"award-number":["T-2021-915"]}]},{"name":"Sivas Cumhuriyet \u00dcniversitesi,T\u00fcrkiye","award":["T-2021-915"],"award-info":[{"award-number":["T-2021-915"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02942-8","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T06:21:21Z","timestamp":1753683681000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Investigation of the antitumor activity of lapatinib and NNC 55-0396 dihydrochloride combination in gastric adenocarcinoma"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9127-3201","authenticated-orcid":false,"given":"Muhammed","family":"G\u00f6me\u00e7","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3708-6752","authenticated-orcid":false,"given":"Fatih","family":"Yulak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4303-2996","authenticated-orcid":false,"given":"Mustafa","family":"Erg\u00fcl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"issue":"6","key":"2942_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin"},{"issue":"14","key":"2942_CR2","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1200\/JCO.2005.02.2309","volume":"24","author":"F Kamangar","year":"2006","unstructured":"Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24(14):2137\u201350. https:\/\/doi.org\/10.1200\/JCO.2005.02.2309.","journal-title":"J Clin Oncol"},{"issue":"20","key":"2942_CR3","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa071834","volume":"357","author":"DJ Jonker","year":"2007","unstructured":"Jonker DJ, O\u2019Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au H-J, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357(20):2040\u20138. https:\/\/doi.org\/10.1056\/NEJMoa071834.","journal-title":"N Engl J Med"},{"issue":"4","key":"2942_CR4","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.coph.2013.05.004","volume":"13","author":"M Alamgeer","year":"2013","unstructured":"Alamgeer M, Ganju V, Watkins DN. Novel therapeutic targets in non-small cell lung cancer. Curr Opin Pharmacol. 2013;13(4):394\u2013401. https:\/\/doi.org\/10.1016\/j.coph.2013.05.004.","journal-title":"Curr Opin Pharmacol"},{"issue":"3","key":"2942_CR5","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s11864-012-0193-4","volume":"13","author":"E Smyth","year":"2012","unstructured":"Smyth E, Cunningham D. Targeted therapy for gastric cancer. Curr Treat Options Oncol. 2012;13(3):377\u201389. https:\/\/doi.org\/10.1007\/s11864-012-0193-4.","journal-title":"Curr Treat Options Oncol"},{"key":"2942_CR6","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMp058035","volume":"354","author":"IG Gounaris","year":"2006","unstructured":"Gounaris IG. Trastuzumab in breast cancer. N Engl J Med. 2006;354:640\u20134. https:\/\/doi.org\/10.1056\/NEJMp058035.","journal-title":"N Engl J Med"},{"issue":"1","key":"2942_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S0014-5793(01)03232-7","volume":"513","author":"T Pawson","year":"2002","unstructured":"Pawson T, Raina M, Nash P. Interaction domains: from simple binding events to complex cellular behavior. FEBS Lett. 2002;513(1):2\u201310. https:\/\/doi.org\/10.1016\/S0014-5793(01)03232-7.","journal-title":"FEBS Lett"},{"issue":"5018","key":"2942_CR8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1126\/science.1857985","volume":"253","author":"DR Knighton","year":"1991","unstructured":"Knighton DR, Zheng JH, Ten Eyck LF, Ashford VA, Xuong NH, Taylor SS, et al. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate\u2013dependent protein kinase. Science. 1991;253(5018):407\u201314. https:\/\/doi.org\/10.1126\/science.1857985.","journal-title":"Science"},{"issue":"4","key":"2942_CR9","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1007\/s10637-011-9719-8","volume":"30","author":"Y Kataoka","year":"2012","unstructured":"Kataoka Y, Mukohara T, Tomioka H, Funakoshi Y, Kiyota N, Fujiwara Y, et al. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. Invest New Drugs. 2012;30(4):1352\u201360. https:\/\/doi.org\/10.1007\/s10637-011-9719-8.","journal-title":"Invest New Drugs"},{"issue":"8","key":"2942_CR10","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1111\/cas.14105","volume":"110","author":"T Yoshioka","year":"2019","unstructured":"Yoshioka T, Shien K, Takeda T, et al. Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells. Cancer Sci. 2019;110(8):2549\u201357. https:\/\/doi.org\/10.1111\/cas.14105.","journal-title":"Cancer Sci"},{"issue":"4","key":"2942_CR11","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1111\/cas.13511","volume":"109","author":"T Yoshioka","year":"2018","unstructured":"Yoshioka T, Shien K, Namba K, et al. Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer. Cancer Sci. 2018;109(4):1166\u201376. https:\/\/doi.org\/10.1111\/cas.13511.","journal-title":"Cancer Sci"},{"issue":"23","key":"2942_CR12","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1074\/jbc.270.23.815","volume":"270","author":"CJ Sabers","year":"1995","unstructured":"Sabers CJ, Martin MM, Brunn GJ, et al. Isolation of a protein target of the FKBP12\u2013rapamycin complex in mammalian cells. J Biol Chem. 1995;270(23):815\u201322. https:\/\/doi.org\/10.1074\/jbc.270.23.815.","journal-title":"J Biol Chem"},{"issue":"5","key":"2942_CR13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc1347","volume":"4","author":"M-A Bjornsti","year":"2004","unstructured":"Bjornsti M-A, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004;4(5):335\u201348. https:\/\/doi.org\/10.1038\/nrc1347.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"2942_CR14","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","volume":"124","author":"S Wullschleger","year":"2006","unstructured":"Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124(3):471\u201384. https:\/\/doi.org\/10.1016\/j.cell.2006.01.016.","journal-title":"Cell"},{"key":"2942_CR15","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.1038\/ncomms6477","volume":"5","author":"SS Wong","year":"2014","unstructured":"Wong SS, Kim KM, Ting JC, et al. Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing. Nat Commun. 2014;5:5477. https:\/\/doi.org\/10.1038\/ncomms6477.","journal-title":"Nat Commun"},{"key":"2942_CR16","doi-asserted-by":"publisher","first-page":"12983","DOI":"10.1038\/ncomms12983","volume":"7","author":"WF Ooi","year":"2016","unstructured":"Ooi WF, Xing M, Xu C, et al. Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity. Nat Commun. 2016;7:12983. https:\/\/doi.org\/10.1038\/ncomms12983.","journal-title":"Nat Commun"},{"issue":"10","key":"2942_CR17","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1111\/cas.13325","volume":"108","author":"J Gao","year":"2017","unstructured":"Gao J, Wang H, Zang W, et al. Circulating tumor DNA functions as an alternative for tissue to overcome tumor heterogeneity in advanced gastric cancer. Cancer Sci. 2017;108(10):1881\u20137. https:\/\/doi.org\/10.1111\/cas.13325.","journal-title":"Cancer Sci"},{"issue":"7","key":"2942_CR18","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrm1155","volume":"4","author":"MJ Berridge","year":"2003","unstructured":"Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol. 2003;4(7):517\u201329. https:\/\/doi.org\/10.1038\/nrm1155.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"2942_CR19","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.cell.2007.11.028","volume":"131","author":"DE Clapham","year":"2007","unstructured":"Clapham DE. Calcium signaling. Cell. 2007;131(6):1047\u201358. https:\/\/doi.org\/10.1016\/j.cell.2007.11.028.","journal-title":"Cell"},{"issue":"7","key":"2942_CR20","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nrc2171","volume":"7","author":"GR Monteith","year":"2007","unstructured":"Monteith GR, McAndrew D, Faddy HM, Roberts-Thomson SJ. Calcium and cancer: targeting Ca2+ transport. Nat Rev Cancer. 2007;7(7):519\u201330. https:\/\/doi.org\/10.1038\/nrc2171.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2942_CR21","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00424-014-1444-z","volume":"466","author":"B Dziegielewska","year":"2014","unstructured":"Dziegielewska B, Gray LS, Dziegielewski J. T-type calcium channel blockers as new tools in cancer therapies. Pflugers Arch. 2014;466(5):801\u201310. https:\/\/doi.org\/10.1007\/s00424-014-1444-z.","journal-title":"Pflugers Arch"},{"key":"2942_CR22","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejmech.2018.06.048","volume":"156","author":"H Tang","year":"2018","unstructured":"Tang H, Zhang Y, Li D, Fu S, Tang M, Wan L, Chen K, et al. Discovery and synthesis of novel magnolol derivatives with potent anticancer activity in non-small cell lung cancer. Eur J Med Chem. 2018;156:190\u2013205. https:\/\/doi.org\/10.1016\/j.ejmech.2018.06.048.","journal-title":"Eur J Med Chem"},{"key":"2942_CR23","doi-asserted-by":"publisher","first-page":"132318","DOI":"10.1016\/j.molstruc.2021.132318","volume":"1254","author":"M Gome\u00e7","year":"2022","unstructured":"Gome\u00e7 M, Yulak F, Gezegen H, Ozkaraca M, Sayin K, Ataseven H. Synthesis of diaryl urea derivatives and evaluation of their antiproliferative activities in colon adenocarcinoma. J Mol Struct. 2022;1254:132318. https:\/\/doi.org\/10.1016\/j.molstruc.2021.132318.","journal-title":"J Mol Struct"},{"key":"2942_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-024-04587-6","author":"F Yulak","year":"2024","unstructured":"Yulak F, Joha Z, \u00d6zt\u00fcrk A, \u0130nan ZD\u015e, Ta\u015fk\u0131ran A\u015e. Enoxaparin protects C6 glioma cells from glutamate-induced cytotoxicity by reducing oxidative stress and apoptosis. Mol Neurobiol. 2024. https:\/\/doi.org\/10.1007\/s12035-024-04587-6.","journal-title":"Mol Neurobiol"},{"key":"2942_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tiv.2023.105610","volume":"90","author":"GSK Ataseven","year":"2023","unstructured":"Ataseven GSK, Ta\u015ftemur \u015e, Yulak F, Karabulut S, Ergul M. GSK461364A suppresses proliferation of gastric cancer cells and induces apoptosis. Toxicol In Vitro. 2023;90:1\u201310.","journal-title":"Toxicol In Vitro"},{"issue":"12","key":"2942_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12032-023-02221-4","volume":"40","author":"F Yulak","year":"2023","unstructured":"Yulak F, Filiz AK, Joha Z, Ergul M. Mechanism of anticancer effect of ETP-45658, a PI3K\/AKT\/mTOR pathway inhibitor on HT-29 cells. Med Oncol. 2023;40(12):1\u201314.","journal-title":"Med Oncol"},{"issue":"4","key":"2942_CR27","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/01926230701320337","volume":"35","author":"S Elmore","year":"2007","unstructured":"Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495\u2013516. https:\/\/doi.org\/10.1080\/01926230701320337.","journal-title":"Toxicol Pathol"},{"issue":"6","key":"2942_CR28","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1016\/j.bbamem.2016.02.022","volume":"1868","author":"A Girault","year":"2016","unstructured":"Girault A, Haigh K, Micu I, et al. T-type calcium channels in cancer: oncogenic functions and clinical relevance. Biochim Biophys Acta. 2016;1868(6):1669\u201378. https:\/\/doi.org\/10.1016\/j.bbamem.2016.02.022.","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"2942_CR29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.canlet.2011.10.026","volume":"316","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Wang J, Li Q, et al. T-type Ca2+ channel blockade by NNC 55\u20130396 leads to apoptosis in gastric cancer cells. Cancer Lett. 2012;316(2):139\u201346. https:\/\/doi.org\/10.1016\/j.canlet.2011.10.026.","journal-title":"Cancer Lett"},{"issue":"31","key":"2942_CR30","doi-asserted-by":"publisher","first-page":"10360","DOI":"10.1523\/JNEUROSCI.1445-10.2010","volume":"30","author":"W-K Chen","year":"2010","unstructured":"Chen W-K, Liu I-Y, Chang Y-T, et al. Cav3.2 T-type Ca2+ channel-dependent activation of ERK in paraventricular thalamus modulates acid-induced chronic muscle pain. J Neurosci. 2010;30(31):10360. https:\/\/doi.org\/10.1523\/JNEUROSCI.1445-10.2010.","journal-title":"J Neurosci"},{"issue":"8","key":"2942_CR31","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1097\/CAD.0000000000001105","volume":"32","author":"C Alanda\u011f","year":"2021","unstructured":"Alanda\u011f C, Merev E, \u00d6zdemir F. Repurposing calcium channel blockers: may be sensible combination with erlotinib for non-small cell lung cancer. Anti Cancer Drugs. 2021;32(8):882\u20135. https:\/\/doi.org\/10.1097\/CAD.0000000000001105.","journal-title":"Anti Cancer Drugs"},{"issue":"1","key":"2942_CR32","doi-asserted-by":"publisher","first-page":"17608","DOI":"10.1038\/s41598-019-54129-7","volume":"9","author":"MS Hassan","year":"2019","unstructured":"Hassan MS, Williams F, Awasthi N, Schwarz MA, Schwarz RE, Li J, et al. Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma. Sci Rep. 2019;9(1):17608. https:\/\/doi.org\/10.1038\/s41598-019-54129-7.","journal-title":"Sci Rep"},{"issue":"2","key":"2942_CR33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12032-023-02290-5","volume":"41","author":"K Horpratraporn","year":"2024","unstructured":"Horpratraporn K, Adchariyasakulchai P, Sainamthip P, Ketchart W. Combining lapatinib and palbociclib inhibits cell proliferation and invasion via AKT signaling pathway in endocrine-resistant breast cancer cells. Med Oncol. 2024;41(2):58. https:\/\/doi.org\/10.1007\/s12032-023-02290-5.","journal-title":"Med Oncol"},{"issue":"1","key":"2942_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2004.10.021","volume":"226","author":"CQ Li","year":"2005","unstructured":"Li CQ, Wogan GN. Nitric oxide as a modulator of apoptosis. Cancer Lett. 2005;226(1):1\u201315. https:\/\/doi.org\/10.1016\/j.canlet.2004.10.021.","journal-title":"Cancer Lett"},{"key":"2942_CR35","doi-asserted-by":"publisher","first-page":"109288","DOI":"10.1016\/j.cbi.2020.109288","volume":"332","author":"M Ergul","year":"2020","unstructured":"Ergul M, Bakar-Ates F. A specific inhibitor of polo-like kinase 1, GSK461364A, suppresses proliferation of Raji Burkitt\u2019s lymphoma cells through mediating cell cycle arrest, DNA damage, and apoptosis. Chem Biol Interact. 2020;332:109288. https:\/\/doi.org\/10.1016\/j.cbi.2020.109288.","journal-title":"Chem Biol Interact"},{"key":"2942_CR36","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/1756-9966-30-87","volume":"30","author":"RS Wong","year":"2011","unstructured":"Wong RS. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 2011;30:87. https:\/\/doi.org\/10.1186\/1756-9966-30-87.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2942_CR37","doi-asserted-by":"publisher","first-page":"e2058","DOI":"10.1038\/cddis.2015.275","volume":"7","author":"S Baig","year":"2016","unstructured":"Baig S, Seevasant I, Mohamad J, Mukheem A, Huri HZ, Kamarul T. Potential of apoptotic pathway-targeted cancer therapeutic research: where do we stand? Cell Death Dis. 2016;7(1):e2058. https:\/\/doi.org\/10.1038\/cddis.2015.275.","journal-title":"Cell Death Dis"},{"issue":"2","key":"2942_CR38","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4161\/cbt.4.2.1508","volume":"4","author":"Z Jin","year":"2005","unstructured":"Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther. 2005;4(2):139\u201363. https:\/\/doi.org\/10.4161\/cbt.4.2.1508.","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"2942_CR39","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s11523-019-00680-2","volume":"14","author":"E Sachdev","year":"2019","unstructured":"Sachdev E, Tabatabai R, Roy V, Rimel BJ, Mita MM. PARP inhibition in cancer: an update on clinical development. Target Oncol. 2019;14(6):657\u201379. https:\/\/doi.org\/10.1007\/s11523-019-00680-2.","journal-title":"Target Oncol"},{"key":"2942_CR40","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/978-3-642-54490-3_7","volume":"201","author":"M Nolting","year":"2014","unstructured":"Nolting M, Schneider-Merck T, Trepel M. Lapatinib. Recent Results Cancer Res. 2014;201:125\u201343. https:\/\/doi.org\/10.1007\/978-3-642-54490-3_7.","journal-title":"Recent Results Cancer Res"},{"issue":"21","key":"2942_CR41","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1158\/1078-0432.CCR-18-0549","volume":"24","author":"S Arai","year":"2018","unstructured":"Arai S, Jonas O, Whitman MA, Corey E, Balk SP, Chen S, et al. Tyrosine kinase inhibitors increase MCL1 degradation and in combination with BCLXL\/BCL2 inhibitors drive prostate cancer apoptosis. Clin Cancer Res. 2018;24(21):5458\u201370. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0549.","journal-title":"Clin Cancer Res"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02942-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02942-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02942-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T04:03:14Z","timestamp":1757304194000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02942-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":41,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["2942"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02942-8","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"10 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"384"}}